Common Contracts
2 similar Revenue Interest Financing Agreement contracts by Liquidia Corp
THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • March 13th, 2024 • Liquidia Corp • Pharmaceutical preparations
This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of July 27, 2023 (the “Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • August 10th, 2023 • Liquidia Corp • Pharmaceutical preparations
This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of July 27, 2023 (the “Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Investor Representative under the Agreement (as defined below) (the “Investor Representative”), solely with respect to certain enumerated provisions in the Agreement described herein. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
